SCHEMBL288689

SCHEMBL288689

NCCC[C@@H](N)CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.46
LMNA P02545 3/20 0.44
GABRR1 P24046 3/20 0.44
THRB P10828 2/20 0.44
BLM P54132 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GABRR3 A8MPY1 1/20 0.44
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
HDAC3 O15379 1/20 0.44
GABBR2 O75899 1/20 0.44
CYP1A2 P05177 1/20 0.44
GABRA1 P14867 1/20 0.44
TSHR P16473 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRR2 P28476 1/20 0.44
SLC6A1 P30531 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL562061 1.00 GSR (0.46) GSRLMNAGABRR1THRBBLM
SCHEMBL159650 1.00 GSR (0.46) GSRLMNAGABRR1THRBBLM
SCHEMBL60354 1.00 GSR (0.46) GSRLMNAGABRR1THRBBLM
Ammonia Solution, Strong SCHEMBL8677036 0.98 GSR (0.45) GSRLMNAGABRR1THRBBLM
Hydrochloric Acid SCHEMBL31510869 0.98 GSR (0.45) GSRLMNAGABRR1THRBBLM
SCHEMBL30514395 0.93 GSR (0.56) GSRLMNAGABRR1THRBBLM
SCHEMBL284983 0.93 GSR (0.56) GSRLMNAGABRR1THRBBLM
SCHEMBL289144 0.93 GSR (0.56) GSRLMNAGABRR1THRBBLM
Propionic Acid SCHEMBL29234998 0.92 S1PR2 (0.45) GSRLMNAGABRR1THRBBLM
SCHEMBL288798 0.91 GSR (0.54) GSRLMNAGABRR1THRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250180578-A1 METHODS FOR IDENTIFYING MODIFICATIONS OF A POLYPEPTIDE NAUTILUS SUBSIDIARY INC (US) 2025-06-05 US claimed
CN-119409964-A Epsilon-poly-L-lysine derivative with click function, preparation method and application thereof 公立大学法人福井县立大学 2025-02-11 CN claimed
US-20240402186-A1 SYSTEMS AND METHODS FOR BIOMOLECULE QUANTITATION NAUTILUS SUBSIDIARY INC (US) 2024-12-05 US claimed
CN-118125936-A N-acyl ethanolamide derivative, preparation method and application thereof 南京清普生物科技有限公司 2024-06-04 CN claimed
EP-4096715-A1 COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF Flagship Pioneering Innovations VI, LLC (US) 2022-12-07 EP claimed
US-20220305128-A1 COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF FLAGSHIP PIONEERING INNOVATIONS VI, LLC 2022-09-29 US claimed
EP-3986469-A1 COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF Flagship Pioneering Innovations VI, LLC (US) 2022-04-27 EP claimed
WO-2021155177-A1 COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2021-08-05 WO claimed
WO-2020257730-A1 COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2020-12-24 WO claimed
CN-107913246-A The medical composite for eye of local administration 刘力 2018-04-17 CN claimed
US-20120301950-A1 BIOLOGICAL SYNTHESIS OF DIFUNCTIONAL HEXANES AND PENTANES FROM CARBOHYDRATE FEEDSTOCKS CELEXION, LLC 2012-11-29 US claimed
CN-102124119-A Production process for fine chemicals using microorganisms with reduced isocitrate dehydrogenase activity BASF SE 2011-07-13 CN claimed
US-20100184210-A1 METHOD FOR ISOLATING CELLS MERCK PATENT GESELLSCHAFT (DE) 2010-07-22 US claimed
EP-2049677-A1 METHOD FOR ISOLATING CELLS MERCK PATENT GmbH (DE) 2009-04-22 EP claimed
CN-101400799-A Method for producing beta-lysine BASF SE (DE) 2009-04-01 CN claimed
WO-2008017097-A1 METHOD FOR ISOLATING CELLS MERCK PATENT GMBH (DE) 2008-02-14 WO claimed
WO-2007047680-A2 INCREASING THE ACTIVITY OF RADICAL S-ADENOSYL METHIONINE (SAM) ENZYMES CARGILL, INCORPORATED (US) 2007-04-26 WO claimed
EP-0134563-B1 NOVEL AMINOGLYCOSIDE COMPOUNDS AND THEIR ACID ADDITION SALTS AND PROCESS FOR PRODUCTION THEREOF KOWA COMPANY, LTD. (JP) 1988-10-19 EP claimed
US-4647656-A ANTIBIOTICS KOWA COMPANY, LTD. (JP) 1987-03-03 US claimed
EP-0134563-A1 Novel aminoglycoside compounds and their acid addition salts and process for production thereof KOWA COMPANY, LTD. (JP) 1985-03-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220305128-A1 COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF RNMT, NSUN3, NSUN2 GSR 3278/4885LMNA 1365/4885GABRR1 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.